https://obsidiantx.com/publications_posts/obx-115-membrane-bound-il15-mbil15-expressing-engineered-tumor-infiltrating-lymphocytes-til-overcome-target-cell-immune-evasion-related-to-major-histocompatibility-complex-mhc-silencing-through/ 2026-07-16T22:24:24+00:00 https://obsidiantx.com/publications_posts/translational-data-validate-obx-115-mechanism-of-action-impact-of-dosing-on-clinical-outcome-in-advanced-melanoma-2/ 2026-07-16T22:24:24+00:00 https://obsidiantx.com/publications_posts/translational-data-validate-obx%e2%80%90115-mechanism-of-action-impact-of-dosing-on-clinical-outcome-in-advanced-melanoma/ 2026-07-16T22:24:25+00:00 https://obsidiantx.com/publications_posts/obx-115-engineered-tumor-infiltrating-lymphocyte-til-cell-therapy-with-regulatable-membrane-bound-il15-mbil15-in-patients-with-immune-checkpoint-inhibitor-ici-resistant-advanced-melanoma/ 2026-07-16T22:24:25+00:00 https://obsidiantx.com/publications_posts/translational-data-validate-obx-115-mechanism-of-action-impact-of-dosing-on-clinical-outcome-in-advanced-melanoma/ 2026-07-16T22:24:25+00:00 https://obsidiantx.com/publications_posts/obx-115-engineered-tumor-infiltrating-lymphocytes-til-with-regulatable-membrane-bound-il15-mbil15-translational-data-from-a-single-center-phase-1-trial-in-patients-with-immune-checkpoint-inhibito/ 2026-07-16T22:24:26+00:00 https://obsidiantx.com/publications_posts/trial-in-progress-phase-1-2-study-of-obx-115-engineered-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-solid-tumors/ 2026-07-16T22:24:26+00:00 https://obsidiantx.com/publications_posts/obx-115-til-from-non-small-cell-lung-cancer-nsclc-are-enriched-for-putative-tumor-reactive-stem-like-t-cells-with-enhanced-tumor-cytotoxicity-results-from-multimodal-phenotypic-analysis/ 2026-07-16T22:24:26+00:00 https://obsidiantx.com/publications_posts/spatiotemporally-regulated-expression-of-membrane-bound-interleukin-12-mbil12-for-armored-adoptive-cell-therapy-act-shows-strong-antitumor-activity-in-syngeneic-solid-tumor-models-without-overt-to/ 2026-07-16T22:24:27+00:00 https://obsidiantx.com/publications_posts/il2-independent-expansion-persistence-and-antitumor-activity-in-til-expressing-regulatable-membrane-bound-il15/ 2026-07-16T22:24:27+00:00 https://obsidiantx.com/publications_posts/entering-a-new-era-of-til-cell-therapy-innovation/ 2026-07-16T22:24:27+00:00 https://obsidiantx.com/publications_posts/antigen-responsive-promoters-coupled-with-cytodrive-technology-provides-tight-spatiotemporal-regulation-for-tumor-infiltrating-lymphocytes-til-expressing-membrane-bound-il12-mbil12/ 2026-07-16T22:24:28+00:00 https://obsidiantx.com/publications_posts/feasibility-of-using-core-needle-biopsy-technique-for-minimally-invasive-tumor-procurement-to-generate-obx-115-til-from-nsclc-tumors/ 2026-07-16T22:24:28+00:00 https://obsidiantx.com/publications_posts/carbonic-anhydrase-2-derived-drug-responsive-domain-regulates-membrane-bound-cytokine-expression-and-function-in-engineered-t-cells/ 2026-07-16T22:24:28+00:00 https://obsidiantx.com/publications_posts/engineered-tumor-infiltrating-lymphocytes-til-with-membrane-bound-il15-mbil15-and-light-tnfsf14-generate-significant-antitumor-efficacy-in-fibrotic-tumor-models/ 2026-07-16T22:24:29+00:00 https://obsidiantx.com/publications_posts/trial-in-progress-a-phase-1-2-study-to-investigate-the-safety-and-efficacy-of-obx-115-engineered-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-solid-tumors-agni-01-3/ 2026-07-16T22:24:29+00:00 https://obsidiantx.com/publications_posts/obx-115-an-interleukin-2-il2-sparing-engineered-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-immune-checkpoint-inhibitor-ici-resistant-unresectable-or-metastatic-melanoma/ 2026-07-16T22:24:30+00:00 https://obsidiantx.com/publications_posts/trial-in-progress-a-phase-1-2-study-to-investigate-the-safety-and-efficacy-of-obx-115-engineered-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-solid-tumors-agni-01-2/ 2026-07-16T22:24:30+00:00 https://obsidiantx.com/publications_posts/minimally-invasive-tumor-tissue-procurement-is-feasible-for-clinical-manufacturing-of-obx-115-engineered-tumor-infiltrating-lymphocytes-til/ 2026-07-16T22:24:30+00:00 https://obsidiantx.com/publications_posts/trial-in-progress-a-phase-1-2-study-to-investigate-the-safety-and-efficacy-of-obx-115-engineered-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-advanced-solid-tumors-agni-01/ 2026-07-16T22:25:04+00:00 https://obsidiantx.com/publications_posts/trial-in-progress-a-phase-1-2-study-to-investigate-the-safety-and-efficacy-of-obx-115-engineered-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-pts-with-immune-checkpoint-inhibitor-i/ 2026-07-16T22:25:05+00:00 https://obsidiantx.com/publications_posts/obx-115-engineered-tumor-infiltrating-lymphocyte-til-cell-therapy-induced-deepening-and-durable-responses-without-interleukin-2-il2-in-patients-with-immune-checkpoint-inhibitor-ici-resistant-unr/ 2026-07-16T22:25:05+00:00 https://obsidiantx.com/publications_posts/tumor-infiltrating-lymphocytes-til-engineered-with-regulatable-membrane-bound-il15-mbil15-and-light-tnfsf14-show-enhanced-efficacy-in-fibroblast-containing-cold-tumors/ 2026-07-16T22:25:05+00:00 https://obsidiantx.com/publications_posts/trial-in-progress-a-phase-1-2-study-to-investigate-the-safety-and-efficacy-of-obx-115-engineered-tumor-infiltrating-lymphocyte-til-cell-therapy-in-patients-with-immune-checkpoint-inhibitor-ici-re/ 2026-07-16T22:25:06+00:00 https://obsidiantx.com/publications_posts/til-engineered-with-membrane-bound-il15-cytotil15-are-enriched-for-tumorassociated-antigen-reactivity-and-demonstrate-pharmacologically-tunable-expansion-and-persistence-in-the-presence-of/ 2026-07-16T22:25:06+00:00 https://obsidiantx.com/publications_posts/tumor-infiltrating-lymphocytes-til-engineered-with-membrane-bound-il15-cytotil15-cells-exhibit-pharmacologically-regulatable-signal-transduction-in-cis-and-trans/ 2026-07-16T22:25:06+00:00 https://obsidiantx.com/publications_posts/precise-and-titratable-regulation-of-gene-editing-activity-of-a-small-cas9-nuclease-by-an-fda-approved-small-molecule-drug-using-cytodrive-technology/ 2026-07-16T22:25:07+00:00 https://obsidiantx.com/publications_posts/il15-engineered-tumor-infiltrating-lymphocytes-cytotil15-exhibit-activity-against-autologous-tumor-cells-from-multiple-solid-tumor-indications-without-il2/ 2026-07-16T22:25:07+00:00 https://obsidiantx.com/publications_posts/engineering-tumor-infiltrating-lymphocytes-from-sarcoma-and-colorectal-tumors-with-membrane-bound-il15-for-il2-independent-expansion-and-enhanced-cytotoxicity-against-autologous-tumor-cell-lines/ 2026-07-16T22:25:08+00:00 https://obsidiantx.com/publications_posts/armoring-tumor-infiltrating-lymphocytes-til-with-regulatable-membrane-bound-il15-for-increased-persistence-and-potency-without-the-use-of-concomitant-il2/ 2026-07-16T22:25:08+00:00 https://obsidiantx.com/publications_posts/enhancers-of-innate-and-adaptive-immunity-combine-with-membrane-bound-il15-to-increase-the-efficacy-of-tumor-infiltrating-lymphocyte-til-therapy-for-tumors-with-immunosuppressive-microenvironments/ 2026-07-16T22:25:08+00:00 https://obsidiantx.com/publications_posts/digital-spatial-profiling-and-antigen-dependent-phenotypic-analysis-of-il15-engineered-tumor-infiltrating-lymphocytes-cytotil15tm-therapy-in-an-allogeneic-melanoma-pdx-model/ 2026-07-16T22:25:08+00:00 https://obsidiantx.com/publications_posts/pharmacologically-controlled-expression-of-membrane-bound-il-12-results-in-t-cell-therapy-with-enhanced-potency-in-preclinical-solid-tumor-models/ 2026-07-16T22:25:09+00:00 https://obsidiantx.com/publications_posts/armoring-t-cells-with-regulatable-membrane-tethered-cytokines-using-improved-drug-responsive-domain-cytodrive-technology/ 2026-07-16T22:25:09+00:00 https://obsidiantx.com/publications_posts/genetically-engineered-tumor-infiltrating-lymphocytes-cytotil15-exhibit-il2-independent-persistence-and-anti-tumor-efficacy-against-melanoma-in-vivo-10/ 2026-07-16T22:25:10+00:00 https://obsidiantx.com/publications_posts/novel-drug-responsive-domain-drd-based-regulation-technology-enables-tightly-controlled-activity-of-potent-membrane-bound-il-12-in-adoptive-cell-therapies/ 2026-07-16T22:25:10+00:00 https://obsidiantx.com/publications_posts/allogeneic-il-2-independent-tumor-infiltrating-lymphocytes-expressing-membrane-bound-il-15-cytotil15-eradicate-tumors-in-a-melanoma-pdx-model-through-recognition-of-shared-tumor-antigens/ 2026-07-16T22:25:10+00:00 https://obsidiantx.com/publications_posts/genetically-engineered-tumor-infiltrating-lymphocytes-cytotil15-exhibit-il2-independent-persistence-and-anti-tumor-efficacy-against-melanoma-in-vivo-6/ 2026-07-16T22:25:11+00:00 https://obsidiantx.com/publications_posts/genetically-engineered-tumor-infiltrating-lymphocytes-cytotil15-exhibit-il2-independent-persistence-and-anti-tumor-efficacy-against-melanoma-in-vivo-13/ 2026-07-16T22:25:11+00:00 https://obsidiantx.com/publications_posts/genetically-engineered-tumor-infiltrating-lymphocytes-cytotil15-exhibit-il2-independent-persistence-and-anti-tumor-efficacy-against-melanoma-in-vivo-12/ 2026-07-16T22:25:11+00:00 https://obsidiantx.com/publications_posts/genetically-engineered-tumor-infiltrating-lymphocytes-cytotil15-exhibit-il2-independent-persistence-and-anti-tumor-efficacy-against-melanoma-in-vivo-11/ 2026-07-16T22:25:11+00:00 https://obsidiantx.com/publications_posts/genetically-engineered-tumor-infiltrating-lymphocytes-cytotil15-exhibit-il2-independent-persistence-and-anti-tumor-efficacy-against-melanoma-in-vivo-9/ 2026-07-16T22:25:12+00:00 https://obsidiantx.com/publications_posts/genetically-engineered-tumor-infiltrating-lymphocytes-cytotil15-exhibit-il2-independent-persistence-and-anti-tumor-efficacy-against-melanoma-in-vivo-8/ 2026-07-16T22:25:12+00:00 https://obsidiantx.com/publications_posts/genetically-engineered-tumor-infiltrating-lymphocytes-cytotil15-exhibit-il2-independent-persistence-and-anti-tumor-efficacy-against-melanoma-in-vivo-7/ 2026-07-16T22:25:12+00:00 https://obsidiantx.com/publications_posts/obx-115-engineered-tumor-infiltrating-lymphocyte-til-cell-therapy-with-regulatable-membrane-bound-il15-mbil15-in-patients-with-immune-checkpoint-inhibitor-ici-resistant-advanced-melanoma-2/ 2026-07-21T21:13:15+00:00